Proactive Investors - Run By Investors For Investors

Achieve Life Sciences to begin Phase 2b trial for its smoking cessation drug

The data results of the study are expected to be made available in mid-2019
A put out cigarette
Its drug interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms

Achieve Life Sciences Inc (NASDAQ:ACHV) shares soared double digits following the announcement that it will begin its Phase 2b trial for Cytisinicline, its smoking cessation drug.

Known as its Ongoing Research of Cytisinicline for Addiction Program, or ORCA, the trial will evaluate the effectiveness of the drug on smoking cessation.

READ: Achieve Life Sciences shares climb following positive results from its smoking cessation study

Shares of the Washington State-based biotech jumped more than 20% to $2.52 in Tuesday Morning trading.

The randomized study will look at 1.5mg and 3mg  doses of cytisinicline over 25 days, as well as three times daily dosing.

The plant-based compound, also known as cytisine, interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms.

The effectiveness of the trial will be determined by the reduction in the number of cigarettes smoked during treatment.

A total of 250 smokers will participate in a study being conducted across eight US centers.

“We intend to utilize our learnings from this trial to finalize the Phase 3 program, expected to begin later next year,”  said CEO Rick Stewart in the company’s press release.

The data results are expected to be made available in mid-2019.

The company also announced that the United States Adopted Names Council adopted "cytisinicline" as the generic name for cytisine.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full ACHV profile View Profile

Achieve Life Sciences Inc Timeline

Related Articles

Kazakhstan
November 20 2018
Borko Moric will succeed Parilla as chief executive officer. Bojan Moric will become the company's chief operations officer
Platinum
January 04 2019
In its outlook for 2019, the firm said the focus was now “not only on continuous improvements in feed grade and recoveries but on expanding the business into new jurisdictions”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use